Literature DB >> 17484483

[Unilateral essential hematuria: diagnosis, endoscopic treatment, and new diagnostic-therapeutic algorithm].

Alvaro Serrano1, Inmaculada Fernández, Pilar González-Peramato, Ignacio Otero, Javier Regadera, Jesús Golbano, Francisco Lovaco.   

Abstract

OBJECTIVES: To perform a long-term evaluation of 15 patients with unilateral essential hematuria, with the aim of determining the causes of bleeding and the response to endoscopic treatment. To design a diagnostic-therapeutic algorithm for patients with unilateral essential hematuria.
METHODS: We retrospectively review the clinical data of 15 patients with unilateral essential hematuria evaluated by rigid ureterorenoscopy (15 cases), flexible ureteropyelocalycoscopy (15 cases) and percutaneous nephroscopy (3 cases). In 4 patients electric fulguration of the pyelocalicial lesions was carried out.
RESULTS: 14 of the 15 patients were successfully treated endoscopically. Only one patient presented recurrence of the hematuria. Mean follow-up time was 64 months (4-168 months). No patient suffered any relevant complication secondary to the endoscopic treatment.
CONCLUSIONS: The cause of bleeding in patients with unilateral essential hematuria is determined only in a few, but endoscopic treatment is successful in a high percentage of cases. We consider that upper urinary tract endoscopy, mainly flexible ureteropyelocalycoscopy, has strongly impacted the diagnosis and treatment of essential unilateral hematuria. We present a new diagnostic-therapeutic algorithm, based on the usefulness of flexible instrumentation.

Entities:  

Mesh:

Year:  2007        PMID: 17484483     DOI: 10.4321/s0004-06142007000200007

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  1 in total

1.  Ureteroscopic management of chronic unilateral hematuria: a single-center experience over 22 years.

Authors:  Motoo Araki; Shinya Uehara; Katsumi Sasaki; Koichi Monden; Masaya Tsugawa; Toyohiko Watanabe; Manoji Monga; Yasutomo Nasu; Hiromi Kumon
Journal:  PLoS One       Date:  2012-06-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.